Credit Suisse Ag Ovid Therapeutics Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$2.42 - $4.47 $35,254 - $65,118	-14,568 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.28 - $6.84 $33,215 - $99,645	14,568 New	14,568 $33,000
Q2 2020 Aug 12, 2020	SELL	$2.67 - $7.91 $31,361 - $92,910	-11,746 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$2.03 - $4.35 $528,648 - $1.13 Million	-260,418 Reduced 95.68%	11,746 $35,000
Q4 2019 Feb 12, 2020	BUY	$2.08 - $5.06 $566,101 - $1.38 Million	272,164 New	272,164 $1.13 Million

39M

37.4K

500

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $67.6M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.